Vancouver, British Columbia--(Newsfile Corp. - December 17, 2020) - Arch Biopartners (TSXV: ARCH) (OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, has been awarded a contribution of up to $6.7 million from the Government of Canada. The funding comes from the department of...